Cantor Fitzgerald Maintains Overweight on Stoke Therapeutics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Stoke Therapeutics (NASDAQ:STOK) and raises the price target from $20 to $25.
May 23, 2023 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Stoke Therapeutics and raises the price target from $20 to $25.
The news of Cantor Fitzgerald maintaining an Overweight rating on Stoke Therapeutics and raising the price target from $20 to $25 is positive for the company. This indicates that the analyst has a bullish outlook on the stock, which could lead to an increase in investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100